First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose.
Drugs and pharma giants Pfizer...
Omicron has a substantial growth advantage over the Delta strain of COVID-19 and is rapidly replacing Delta globally, particularly because it is able to...
Relying solely on the Chinese-manufactured Sinovac inactive vaccine is not enough to reduce transmission rates of COVID-19. Millions of people in 48 countries around...
The failure of the monsoon to bring safe air to the majority of cities in July 2026 is a reminder that clean air remains a distant goal for most urban Indians.